Ignite Creation Date:
2024-05-06 @ 7:29 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06029998
Status:
RECRUITING
Last Update Posted:
2024-03-13
First Post:
2023-09-01
Brief Title:
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
Sponsor:
University of Utah
Organization:
University of Utah
Study Overview
Official Title:
A Phase II Study of Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BORXPTEN
Brief Summary:
The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer mCRPC with PTEN Deletion
The main questions it aims to answer is if the use of bortezomib will result in a decline in PSA for participants
Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles Each cycle is about 21 days
The main questions it aims to answer is if the use of bortezomib will result in a decline in PSA for participants
Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles Each cycle is about 21 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None